Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aljurf, M. D.
Right arrow Articles by Tbakhi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aljurf, M. D.
Right arrow Articles by Tbakhi, A.
Related Collections
Right arrow 2003 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1595-1606, 2003
© 2003 European Society for Medical Oncology

Antigen- and/or immune-driven lymphoproliferative disorders

M. D. Aljurf1,+, T. W. Owaidah2, A. Ezzat1, E. Ibrahim1 and A. Tbakhi1,2

Departments of 1 Oncology and 2 Pathology & Laboratory of Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

Received 3 September 2002; revised 3 February 2003; accepted 3 April 2003

Key words: infection, lymphoma, lymphoproliferative disorder

The first 150 words of the full text of this article appear below.

Introduction

Several lymphoproliferative disorders (LPDs) are believed to be instigated by transformation of a polyclonal population of normal lymphocytes to monoclonal neoplastic disorders in response to antigenic and/or immunological perpetrators [1–3]. The list of antigenic and immunological factors, as well as the corresponding lymphoma entities, is growing steadily [4–10]. In most of the antigen- and/or immune-driven lymphoproliferative disorders (AID-LPD), while the progression is a multistep process, the point at which a non-neoplastic lesion becomes neoplastic is not always precisely defined. Some of these lesions have a clonal abnormality that remains responsive to normal regulators of growth and differentiation, where the point of ‘clonal no return’ will be hard to define. The proliferations of the clones might be subclinical until additional genetic changes occur, where the process frequently becomes irreversible [11, 12]. The hypothesis of a multistep process is further established . . . [Full Text of this Article]

Animal models

AID-LPD: proposed classification

I. Infection related

1. Virus-associated LPD
2. Bacteria-associated LPD
3. Parasite-associated LPD
II. Immune-related LPD

1. Sjogren’s syndrome-associated marginal zone B-cell lymphoma
2. Gluten sensitivity or enteropathy-associated T-cell lymphoma
III. Infection- and/or immune-related LPD

1. Gamma/delta T-cell lymphoma
2. T-cell LGL
3. Other extranodal marginal zone lymphoma of MALT
IV. Others

Drug-associated lymphoid proliferation
Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
M. T. Audicana and M. W. Kennedy
Anisakis simplex: from Obscure Infectious Worm to Inducer of Immune Hypersensitivity
Clin. Microbiol. Rev., April 1, 2008; 21(2): 360 - 379.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Suarez, O. Lortholary, O. Hermine, and M. Lecuit
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Blood, April 15, 2006; 107(8): 3034 - 3044.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia
Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus
J. Virol., December 15, 2004; 78(24): 13891 - 13900.
[Abstract] [Full Text] [PDF]